A detailed history of Amalgamated Bank transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 16,376 shares of SUPN stock, worth $559,240. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,376
Previous 16,817 2.62%
Holding current value
$559,240
Previous $574,000 23.69%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$25.99 - $33.85 $11,461 - $14,927
-441 Reduced 2.62%
16,376 $438,000
Q1 2024

Apr 23, 2024

SELL
$27.11 - $35.17 $164,259 - $213,095
-6,059 Reduced 26.49%
16,817 $574,000
Q4 2023

Feb 06, 2024

SELL
$22.72 - $29.68 $11,473 - $14,988
-505 Reduced 2.16%
22,876 $662,000
Q3 2023

Nov 08, 2023

SELL
$27.57 - $32.91 $18,554 - $22,148
-673 Reduced 2.8%
23,381 $645,000
Q2 2023

Aug 11, 2023

BUY
$29.91 - $38.73 $54,496 - $70,566
1,822 Added 8.2%
24,054 $723,000
Q1 2023

May 02, 2023

SELL
$34.93 - $42.03 $63,607 - $76,536
-1,821 Reduced 7.57%
22,232 $805,000
Q4 2022

Feb 10, 2023

BUY
$31.09 - $37.88 $12,933 - $15,758
416 Added 1.76%
24,053 $858,000
Q3 2022

Nov 09, 2022

BUY
$28.79 - $35.41 $5,412 - $6,657
188 Added 0.8%
23,637 $800,000
Q2 2022

Aug 15, 2022

BUY
$25.33 - $34.25 $1,773 - $2,397
70 Added 0.3%
23,449 $678,000
Q1 2022

Jun 30, 2022

SELL
$28.51 - $32.9 $33,271 - $38,394
-1,167 Reduced 4.75%
23,379 $756,000
Q4 2021

Feb 15, 2022

SELL
$26.37 - $34.22 $15,637 - $20,292
-593 Reduced 2.36%
24,546 $716,000
Q3 2021

Oct 29, 2021

SELL
$23.54 - $31.39 $11,181 - $14,910
-475 Reduced 1.85%
25,139 $670,000
Q2 2021

Aug 16, 2021

BUY
$26.72 - $33.19 $684,406 - $850,128
25,614 New
25,614 $789,000
Q1 2020

May 13, 2020

SELL
$14.45 - $24.69 $135,526 - $231,567
-9,379 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$19.93 - $29.13 $2,331 - $3,408
117 Added 1.26%
9,379 $222,000
Q3 2019

Nov 13, 2019

SELL
$25.47 - $33.37 $2,394 - $3,136
-94 Reduced 1.0%
9,262 $255,000
Q2 2019

Aug 14, 2019

BUY
$29.96 - $38.87 $43,681 - $56,672
1,458 Added 18.46%
9,356 $310,000
Q1 2019

May 15, 2019

BUY
$32.77 - $41.99 $5,833 - $7,474
178 Added 2.31%
7,898 $277,000
Q4 2018

Feb 15, 2019

BUY
$30.84 - $49.51 $238,084 - $382,217
7,720 New
7,720 $256,000
Q3 2018

Nov 14, 2018

SELL
$42.7 - $56.55 $341,898 - $452,795
-8,007 Closed
0 $0
Q2 2018

Jul 18, 2018

BUY
$44.1 - $59.85 $45,334 - $61,525
1,028 Added 14.73%
8,007 $479,000
Q1 2018

May 22, 2018

SELL
$37.15 - $46.9 $3,826 - $4,830
-103 Reduced 1.45%
6,979 $320,000
Q4 2017

Feb 13, 2018

BUY
$36.4 - $42.6 $19,765 - $23,131
543 Added 8.3%
7,082 $282,000
Q3 2017

Nov 09, 2017

BUY
$36.75 - $49.65 $240,308 - $324,661
6,539
6,539 $262,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.83B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.